🔴 Capricor Therapeutics is trading 6.05% down — no clear company-specific catalyst identified

Capricor Therapeutics is trading at $6.83, down 6.05%, with no clear company-specific catalyst identified for the October 16 decline.

• Recent coverage focuses on deramiocel data presented at the World Muscle Society congress and the FDA’s extended review, with a November 22 decision date.
• The supplied sector context shows biotech higher, which does not explain the stock’s decline.
• The move follows a 10.32% gain on October 15.